UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

For the quarterly period ended August 31,November 30, 2010.

or

For the transition period from                              to                             

Commission file number 0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

(517) 372-9200

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) ...    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (see definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):    YES  ¨    NO  x

As of SeptemberDecember 1, 2010, there were 22,733,00023,115,000 shares of Common Stock outstanding.

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

See notes to interim consolidated financial statements

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

See notes to interim consolidated financial statements

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED)

See notes to interim consolidated financial statements

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

See notes to interim consolidated financial statements

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the three and six month periodperiods ended August 31,November 30, 2010 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2011. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2010 audited consolidated financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2010.

2. INVENTORIES

Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:

3. NET INCOME PER SHARE

The calculation of net income per share follows:

The Board of Directors declared a 3 for 2 stock split effective December 15, 2009. All share and per share amounts in this Form 10-Q reflect amounts as if the split took place at the beginning of the periods presented.

4. SEGMENT INFORMATION

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a complete line of consumable products marketed to veterinarians and animal health product distributors and provides genetic identification services. Additionally, the Animal Safety segment produces and markets rodenticides and disinfectants to assist in control of rodents and disease in and around agricultural, food production and other facilities.

Segment information as of and for the three months ended August 31,November 30, 2010 and 2009 follows:

Segment information as of and for the six months ended November 30, 2010 and 2009 follows:

5. EQUITY COMPENSATION PLANS

Options are generally granted under the employee and director stock option plan for 5 years and become exercisable in varying installments. Certain non-qualified options are granted for 10 year periods. A summary of stock option activity during the threesix months ended August 31,November 30, 2010 follows:

During the three monthsand six month periods ended August 31,November 30, 2010 and 2009 the Company recorded $675,000$564,000 and $525,000 and $1,240,000 and $1,050,000, respectively of compensation expense related to its share-based awards.

The weighted-average fair value of stock options granted during 2011 and 2010, estimated on the date of grant using the Black-Scholes option pricing model was $8.52$8.60 and $6.35 respectively. The fair value of stock options granted was estimated using the following weighted-average assumptions.

The Company has 18,00011,250 outstanding warrants that are exercisable for common stock. The warrants have lives of 5 years and were expensed at fair value upon issuance.

The Company has an Employee Stock Purchase plan that provides for employee stock purchases at a 5% discount to market. The discount is expensed as of the date of purchase.

6. NEW ACCOUNTING PRONOUNCEMENTS

Recent ASU’s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

7. BUSINESS AND PRODUCT LINE ACQUISITIONS

On December 1, 2009, the Company purchased the BioKits food safety business of Gen-Probe Incorporated. Consideration for the purchase, which was determined through arms length negotiations, approximated $6.5 million in cash and the assumption of trade accounts payable of $175,000. The preliminary allocation of the purchase price included net current assets of $770,000, fixed assets $163,000 and intangible assets of $5,742,000. The acquired business will operateoperates as a unit of Neogen’s food safety division. Principal products include allergen test kits.

On April 1, 2010, Neogen Corporation acquired GeneSeek, Inc. of Lincoln, Nebraska, a leading commercial agricultural genetic laboratory. GeneSeek’s technology employs high-resolution DNA genotyping for identity and trait analysis in a variety of important animal and agricultural plant species. Consideration for the purchase was $13,800,000 in cash and secondary payment obligations of up to $7,000,000. The preliminary allocation of the purchase price included amountsaccounts receivable of $1,923,000, inventory of $1,212,000, fixed assets of $847,000, current liabilities of $600,000, deferred tax liabilities of $2,050,000, secondary payment liabilities of $3,583,000, based upon future operating results of the GeneSeek business until and is payable yearly over a three year measurement period, and the remainder to goodwill and other intangible assets (with estimated lives of 5-20 years). The secondary payment was measured at fair value, and is considered a level 3 fair value measurement under ASC 820-Fair Value Measurement and Disclosure, as it was based on unobservable inputs and involves management’s judgment. The Company recorded a charge within other income (expense) of approximately $400,000 for the six months ended November 30, 2010, representing the increase in fair value of the secondary payment liability. As of November 30, 2010, the balance of the secondary payment liability recorded was approximately $3,933,000. The acquisition will be integrated into the Animal Safety segment and is expected to be a strong synergistic fit. The Company recorded a charge within other income (expense) of approximately $300,000 for the three months ended August 31, 2010, representing the increase in fair value of the secondary payment liability. As of August 31, 2010, the balance of the secondary payment liability recorded was approximately $3,883,000.

8. LONG TERM DEBT AND LIABILITIES

The Company maintains a financing agreement with a bank (no amounts drawn at August 31,November 30, 2010 or May 31, 2010) providing for an unsecured revolving line of credit of $10,000,000. The interest rate is at LIBOR plus 100 basis points (rate under terms of the agreement was 1.26%1.25% at August 31,November 30, 2010). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the companyCompany was in compliance with at August 31,November 30, 2010.

9. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company is currently expensing annual costs of remediation of approximately $90,000. The Company’s estimated liability for this expense of $916,000 at August 31,November 30, 2010 and May 31, 2010 is recorded within other long termlong-term liabilities in the consolidated balance sheet.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its future results of operations or financial position.

10. STOCK PURCHASE

In December 2008, the Company’s Board of Directors authorized a program to purchase, subject to market conditions, up to 750,000 shares of the company’sCompany’s common stock. As of August 31,November 30, 2010, 74,684 cumulative shares had been purchased in negotiated and open market transactions for a total price, including commissions, of approximately $923,000. There were no purchases in fiscal year 2011 or 2010. Shares purchased under the program were retired.

PART I – FINANCIAL INFORMATION

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial performance.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories, accruals and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to the critical accounting policies and estimates disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2010.

Results of Operations

Executive Overview

Neogen Corporation revenues increased by 33%25% in the firstsecond quarter of FY-11 to $42.9$43.9 million asand by 28% to $86.9 million for the six-month period ended November 30, 2010 when compared to $32.3 million in the first quarter of FY-10. Food Safety revenues increased by 27% and Animal Safety revenues increased by 39%, in comparison with the first quarter of the prior year. Food Safety revenues includedincreased by 16% and 21% in the BioKits acquisition madequarter and in December 2009 andthe six-month period ended November 30, 2010, respectively. Animal Safety revenues were aidedincreased by 34% and 37% in the quarter and in the six-month period ended November 30, 2010, respectively. Exclusive of the revenues that resulted from the BioKits and GeneSeek acquisition,acquisitions, and foreign currency effects overall revenues increased 10% and 13% in April of 2010. The Food Safety Segment reported a 21% increase in organic revenue, while the Animal Safety Segment reported a 7% increase in organic revenues. Sales to international markets were 40% of total revenues.second quarter and year-to-date periods, respectively. Gross margins were unchanged at 53%decreased from 52.5% in both quartersthe November 2009 quarter to 51.2% in the November 2010 quarter and operatingdecreased from 52.9% to 52.1% on a year-to-date basis. The decrease in gross margins was a principally result of less favorable product mix. Operating margins increased in the quarter and six-month periods from 21%20.5% to 22%.21.9% and from 21.0% to 22.1% respectively. The increase in operating marginsgains were athe result of leveraging fixed costsgrowth leverage and controlling expenses.acquisitions as well as continuing cost control efforts.

Revenues

Three and Six Months Ended August 31,November 30, 2010 Compared to Three and Six Months Ended August 31,November 30, 2009

During the first quarter of FY-11, Food Safety revenues increased 27%16% in the second quarter and 21% in the first six months of FY-11. Sales of Natural Toxin, Allergen and Drug Residue products increased by 19% in the quarter and by 21% year-to-date in comparison with FY-10. This sales growth was very broad based across most all market segments and product lines. Organic revenue increased by 21%. Natural Toxins, Allergen and Drug ResiduesExclusive of the BioKits acquisition, revenues increased by 24%,10% and 15% in the quarter and six month periods, in comparison with the prior year quarter. Revenue increases were led by a 98% increase in sales of allergen test kits, due to the acquisitionsame periods of the BioKits product line withprior year. Mycotoxin second quarter revenue growth in sales of test kits to detect milk, egg, almondincreased by 3% and gluten residues. Food processors continue to expand routine testing procedures to help prevent inadvertent contamination from reaching food allergic consumers. Tests for natural toxins grew by 32% in comparison with FY-10 with strong increases in Deoxynivalenol (DON) and histamine test kit sales. DON test kit increases came largely due to continued reports of high levels of mold toxin DON in harvested grain17% in the United States and continued market acceptance of the Company’s new test system. Histamine is a toxin producedsix month period, with difficult comparisons to FY-10, in certain types of harvested fish, especially tuna, if they are improperly stored. Revenue of diagnostic products for bacteria and general sanitation increased 21% in comparison with the prior year quarter. Soleris product lines continued their expansion but with modest growth in placement of new units in comparison with FY-10. Revenue from disposable Soleris test kits continued to increase with a 25% increase in comparison with FY-10. Revenue from dehydrated culture media and other products increased by 43% over the prior year quarter as the Company gained several new customers in this competitive market.

In comparison with the fourth quarter of FY-10, Food Safety revenues increased from $20,815,000 to $22,252,000 in the first quarter of FY-11 and represents a 7% increase. Strong revenue increases came from the Soleris product lines, Neogen Europe and from the Natural Toxin test kit revenues aswhich much of the United States had cool and often wet weather conditions during the summer months and fall harvest seasons resulting in calendara spike in the sales of these products. Revenues from Food Allergen tests continued their recent trend of growth with an overall increase of 87% in the second quarter and 92% in the six months ended November 2010 with strong organic growth combined with the effect of the acquisition of the BioKits product line in December 2009. Testing has continued as this grain has been sold intoDrug residue test kits revenue increased 11% in the marketquarter and 1% in FY-10 and FY-11.

During the first quartersix months of FY-11 Animal Safety revenueas revenues were affected by the strength of the US Dollar in foreign markets. Bacteria and General Sanitation product revenues increased by 39% overall14% in comparisonthe quarter and increased by 18% in the first six months of FY-11 with FY-10. Revenue growth wasmore Soleris capital equipment placements in the current year. Dehydrated Culture Media and Other product revenues increased by 11% and 26% in the quarter and in the six-month periods respectively. These revenue increases were broad based and benefited bycontinued a trend from the acquisition of GeneSeek in the fourth quarter of FY-10. Organic prior quarters.

Animal Safety revenues increased by 7%34% in the second quarter and 37% in the six months ended November 30, 2010 in comparison with the prior year and included contributions from most every product line. Life science and otheryear. Excluding the revenues of the GeneSeek acquisition in April 2010, Animal Safety revenues increased 7% in both the quarter and the first six months of FY-2011. Life Sciences and Other

revenue increased by 11%9% in comparisonboth the quarter and six months respectively. Revenue increases were broad based with FY-10. Components of the life science and other diagnostic test kits used to detect drugs of abuse in forensic applications were 45% higher than the prior year while sales of research diagnostic test kits were up 28% with increased ordersincreases from existing customers and new key accounts. Rodenticide and Disinfectant product revenues increased by 13% in the addition of some new distributors. Vaccinequarter and by 8% on a year-to-date basis. Rodenticide and Disinfectant revenues growth included strong increases in the agronomics segment and a well received fall rodenticide program. Veterinary Instrument and Other product revenues increased by 2% and 7% in FY-11the quarter and six months respectively in comparison with the first three months of FY-10.

Rodenticide and disinfectant revenues increased by 1% in comparison with FY-10. Rodenticide revenues increased by 5%prior year. Increases were due to increased market penetration. The added DuPont products lines have provenstrong OEM and specialty needle revenues, which rebounded from a slow first quarter to be a strong synergistic fit within the Animal Safety product segment but did not experience gainsachieve 93% growth in the first quarter of FY-11. Veterinary instrument and other revenues increased by 12% in comparison with the prior year quarter and included an approximately 35% increase in sales of Ideal veterinary instruments and a 10% increase in sales of the Kane line of disposable OB gloves, supplies and apparel products. Sales of products through over-the-counter distributor channels were led by strong increases in products to treat animal wound, leg and foot conditions.

In comparison with the fourth quarter of FY-10 Animal Safety revenues increased from $18,263,000 to $20,671,000 in the first quarter of FY-11. While the addition of GeneSeek had a significant effect, increasing revenues during the quarter, gains were also made in many of the individual product lines of the Animal Safety Segment.second quarter.

Gross margins decreased from 53.4%52.5% to 51.2% in the second quarter of FY-11 and from 52.9% to 52.1% in the first quartersix months of FY-10 to 53.0% in FY-11. This resulted principally from a changechanges in product mix. mix that included a lower percentage of diagnostic products in relation to overall revenues.

Operating margins in the firstsecond quarter increased from 21.5%20.5% to 21.9% and from 21.0% to 22.1% in the first six months of revenues in FY-10 to 22.4% in FY-11 as a resultcompared to the first six months of gains achieved in revenues without correspondingFY-10. These increases inresulted from increased operating expenses.leverage and continuing cost controls. Sales and marketing expenses as expressed as a percentage of revenues decreased from 18.5%18.2% to 17.5%.17.1% in the second quarter and decreased from 18.3% to 17.3% on a year-to-date basis. The decrease in sales and marketing as a percentage of revenues is the direct effect of the acquisitions during the year that contributed revenue dollars without commensurate increase in distribution costs.cost. General and administrative expenses increased slightlydecreased from 8.9%9.1% to 8.5% of revenues to 9.0%. An absolute dollar increase of $972,000 in the second quarter, and from 9.0% to 8.7% on a year to date basis principally as a result of operating leverage. The change in general and administrative expense, while an increase in absolute dollars of $523,000 in the quarter and $1,494,000 fiscal year-to-date, is due to the increased cost of compensation, employee stock options expense, amortization from acquired businesses and the cost of acquiring businesses with increased amortizationgovernmental licensing and regulatory affairs. Research expense, decreased $57,000 in absolute dollars in the second quarter and increased stock option expense. Research expense, growing $333,000 in absolute dollars,by $277,000 for the first six months of FY-11, decreased as a percent of revenues from 4.5%4.8% to 4.2%. Management believes3.7% in the second fiscal quarter and from 4.7% to 4.0% in the six-month periods. While these expenses vary on a quarter to quarter basis depending on the timing of new projects and the completion of existing projects, management expects that research and development efforts are neededwill range between 4% to 5% in support theof existing products and to increase the supply of future products in key markets and support the Company’s goal to achieve $200 million in revenues by fiscal year 2014. The decrease in percent of revenues resulted directly from the increase in sales in the quarter.

Other income (expense) in FY-11 included $300,000 in other expense as a result of an increase in the expected GeneSeek secondary payment, representing the increase in fair value of the secondary payment liability.products.

Financial Condition and Liquidity

Net cash proceedsProceeds of $628,000$4,871,000 were realized with the exercise of 481,000 stock options and warrants and the issuance of 9,000 shares under the Employee Stock Purchase Plan during the first quarter of FY-11. Due to management efforts, accounts receivable declined in spite ofsix months ended November 30, 2010. Despite increases in revenues, andaccounts receivable increased only $215,000 in the first six months of FY-11, due to continued strong collection efforts. Despite increased operations to support increased revenues, inventories decreased by $213,000 in the six-month period under regimented inventory reduction and control efforts. $11,546,000 in$19,559,000 of cash was generated from operations during the first fiscal quarter of 2011. Inflation and changing prices aredo not expected togenerally have a material effect on operations. As of November 30, 2010, Cash and cash equivalents consisted of funds used to support current operations as management believes it has and will be successful in offsetting increased input costscertificates of deposit and top tier commercial paper with price increases.

maturities of 90 days or less. Management believes that the Company’s existing cash balances at August 31,November 30, 2010, along with available borrowings under its credit facility and cash expected to be generated from future operations, will be sufficient to fund operating needs and acquisition activities for the foreseeable future. However, existing cash and borrowing capacity may notneeds are contingent on future events many of which cannot be sufficient to meet the Company’s cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Company’s mission statement.predicted. Accordingly, the Company may choosebe required to issue equity securities or enter into other financing arrangements for a portion of its future financing needs.

PART I – FINANCIAL INFORMATION

The Company has interest rate and foreign exchange rate risk exposure and no long-term fixed rate investments or borrowings. Primary interest rate risk is due to potential fluctuations of exposure to interest rates for variable rate borrowings.

Foreign exchange risk exposure arises because the Company markets and sells its products throughout the world. It therefore could be affected by weak economic conditions in foreign markets that could reduce demand for its products. Additionally, revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. Dollar. The Company’s operating results are primarily exposed to changes in exchange rates between the U.S. Dollar, the British Pound Sterling and the Euro. When the U.S. Dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. Dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenues in the course of collection can be affected positively or negatively by changes in exchange rates. The Company uses derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the United States that are located in Scotland, Brazil and Mexico where the functional currency is the British Pound Sterling, Brazilian Real and Mexican Peso respectively. The Company’s investment in its foreign subsidiaries are considered long-term.

PART I – FINANCIAL INFORMATION

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of August 31,November 30, 2010 was carried out under the supervision and with the participation of the Company’s management, including the Chairman & Chief Executive Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls Over Financial Reporting – There was no change to the Company’s internal control over financial reporting during the quarter ended August 31,November 30, 2010 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. For purposes of this evaluation, the impact of the acquisition of GeneSeek, Inc. which closed on April 1, 2010, on our internal controls over financial reporting has been excluded.

PART II – OTHER INFORMATION

The Company is subject to certain legal and other proceedings in the normal course of business. In the opinion of management, the outcome of these matters will not have a material effect on its future results of operations or financial position.

(a) Exhibit Index

Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

1415